Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Moderna Inc. entered the new year on the heels ... “(If I) tell you there’s this new biotech company…that has $2 billion of sales, two products approved, $9 billion in the bank, just filed ...

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

ETFs like BBH and IBB reflect biotech gains as investors seek shelter in health care amid rising yields. Daily Moderna Inc. Moderna’s breakout above its 50-day moving average signaled renewed ...

In the third quarter, Moderna reported $1.9 billion in revenue, roughly flat compared to the year-ago period. On the bottom line, the biotech reported net earnings per share of $0.03 compared to a ...